Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Human Papillomavirus-16 Positive Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
Interventions
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced May 22, 2026, 3:51 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma
Interventions
TG4001, Avelumab
Biological · Drug
Lead sponsor
Transgene
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 22, 2026, 3:51 AM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oropharynx
Interventions
ISA101b
Drug
Lead sponsor
ISA Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced May 22, 2026, 3:51 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
HB-201, HB-202, Carboplatin, Paclitaxel, Transoral Robotic Surgery
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma
Interventions
HPV Specific T Cells, Cytoxan, Fludarabine, Nivolumab
Genetic · Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 3:51 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions
DNA vaccination, Gene gun vaccine, intramuscular vaccination, intra-lesional vaccine administration, therapeutic resection of the lesion, imiquimod
Biological · Device · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced May 22, 2026, 3:51 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Lung Cancer, Nonsmall Cell, Melanoma (Skin)
Interventions
Tumor Profiling
Diagnostic Test
Lead sponsor
Repertoire Immune Medicines
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Ann Arbor, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced May 22, 2026, 3:51 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
Drug
Lead sponsor
Theravectys S.A.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced May 22, 2026, 3:51 AM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
BNT113, Pembrolizumab
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
18
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 3:51 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oropharynx, HPV
Interventions
Cetuximab, Radiotherapy
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced May 22, 2026, 3:51 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
E7 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 22, 2026, 3:51 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
Interventions
pNGVL4aCRTE6E7L2
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced May 22, 2026, 3:51 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Metastatic HPV-16 Positive Squamous Cell Anal Cancer
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, Pembrolizumab (KEYTRUDA(R)), Individual Patient TCR-Transduced PBL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced May 22, 2026, 3:51 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
Arm A: RPTR-147:1, Arm B: RPTR-147:1 and Pembrolizumab, Arm C: RPTR-147:2
Biological
Lead sponsor
Repertoire Immune Medicines
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced May 22, 2026, 3:51 AM EDT